Clinical Trials · NCT06027567

The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure

Name: The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 4Semaglutide

Phase: Phase 4
Recruitment status: Completed
Sponsor: Rigmor Højland Jensen
Enrollment: 38
Start date: Sep 2022
Locations: 2 sites, Denmark
Primary endpoint: Weight

View Semaglutide compound reference